12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Company News  |  Deals

Quest Diagnostics, Royalty Pharma deal

Royalty Pharma acquired from diagnostic company Quest Diagnostics the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest said the deal is in line with its strategy announced last year to refocus on its core diagnostic information services business. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >